| Not Yet Recruiting | Decreasing Nightmares in Adults With Narcolepsy NCT06383806 | University of Utah | N/A |
| Not Yet Recruiting | A Study to Evaluate the Efficacy and Safety of E2086 in Adults With Narcolepsy NCT07493265 | Eisai Inc. | Phase 2 |
| Completed | A Study of HBS-201 (Pitolisant Delayed-release) NCT07051252 | Harmony Biosciences Management, Inc. | Phase 1 |
| Terminated | A Study to Investigate Efficacy, Safety, Tolerability, and Pharmacokinetics of JZP441 Compared With Placebo in NCT06961266 | Jazz Pharmaceuticals | Phase 1 |
| Recruiting | The Impact of Light, Electrical, and Magnetic Neuroregulation Interventions on Sleep-wake Disorders NCT06797284 | Second Affiliated Hospital of Soochow University | N/A |
| Not Yet Recruiting | Genetic and Clinical Characterization of Type 1 and 2 Narcolepsy in Adult and Pediatric Black and North Africa NCT06786377 | Assistance Publique - Hôpitaux de Paris | — |
| Recruiting | Study of Psychological, Sociological and Professional Factors Associated With Maintenance of Wakefulness Test NCT06586138 | Hospices Civils de Lyon | — |
| Completed | Observational Study of LUMRYZ in Narcolepsy NCT06792708 | Avadel | — |
| Not Yet Recruiting | Discovering Factors in Narcolepsy Patients' Clinical Research Experiences NCT05870735 | Power Life Sciences Inc. | — |
| Completed | A Study of MK-6552 in Sleep Deprived Healthy Participants (MK-6552-003) NCT06619665 | Merck Sharp & Dohme LLC | Phase 1 |
| Terminated | Study of MK-6552 in Participants With Narcolepsy Type 1 (MK-6552-004) NCT06179407 | Merck Sharp & Dohme LLC | Phase 1 |
| Completed | A Clinical Study of MK-6552 and Modafinil in Healthy Men (MK-6552-005) NCT06665230 | Merck Sharp & Dohme LLC | Phase 1 |
| Completed | A Study to Investigate the Effect of XYWAV on Sleepiness, Polysomnography, and Functional Outcomes in Particip NCT05875974 | Jazz Pharmaceuticals | Phase 4 |
| Recruiting | Unhide® Project: A Digital Health Platform to Collect Lifestyle Data for Brain Inflammation Research NCT04806620 | Brain Inflammation Collaborative | — |
| Completed | A Switch Study From High-Sodium Oxybate to XYWAV to Evaluate Changes in Blood Pressure in Participants With Na NCT05869773 | Jazz Pharmaceuticals | Phase 4 |
| Unknown | Evaluation of Social Cognition in Patient With Type 1 or Type 2 Narcolepsy Versus Patients With Idiopathic Hyp NCT05773872 | Centre Hospitalier Universitaire, Amiens | N/A |
| Completed | Narcolepsy Nightmare Study NCT05709873 | Northwestern University | N/A |
| Unknown | Treating Comorbid Depression of Patients With Narcolepsy by Intermittent Theta Burst Stimulation NCT05884112 | Chang Gung Memorial Hospital | N/A |
| Recruiting | Spectrometry (MRM) Versus I 125 Radioimmunoassay (RIA) for Quantification of Orexin-A of Patients With Hyperso NCT05615584 | University Hospital, Montpellier | N/A |
| Withdrawn | Feasibility Study of At-Home EEG Monitoring for Hypersomnia NCT05627388 | Kaiser Permanente | N/A |
| Recruiting | Proteomics and Metabolomics of Body Fluid in Patients With Narcolepsy NCT06279247 | Qilu Hospital of Shandong University | — |
| Enrolling By Invitation | Cardiovascular and Cognitive Implications of Central Disorders of Hypersomnolence and Their Treatments NCT05371483 | Mayo Clinic | — |
| Recruiting | Mainz Register of Patients With Sleep Disorders NCT05321355 | Johannes Gutenberg University Mainz | — |
| Completed | An Open Label Study of NLS-2 (Mazindol Extended Release) in Subjects With Narcolepsy NCT05055024 | NLS Pharmaceutics | Phase 2 |
| Completed | A Study to Assess the Long-term Efficacy and Safety of AXS-12 (Reboxetine) in Subjects With Narcolepsy (ENCORE NCT05113745 | Axsome Therapeutics, Inc. | Phase 3 |
| Completed | A Study to Assess the Efficacy and Safety of AXS-12 (Reboxetine) in Patients With Narcolepsy NCT05059223 | Axsome Therapeutics, Inc. | Phase 3 |
| Completed | Four-week Study of the Safety and Efficacy of NLS-2 (Mazindol Extended Release) in the Treatment of Narcolepsy NCT04923594 | NLS Pharmaceutics | Phase 2 |
| Completed | Evaluate Sunosi® PK in Breast Milk and Plasma of Healthy Postpartum Women Following Single Dose Oral Administr NCT05008341 | Axsome Therapeutics, Inc. | Phase 1 |
| Recruiting | WAKIX® (Pitolisant) Pregnancy Registry NCT05536011 | Harmony Biosciences Management, Inc. | — |
| Unknown | The Value of Combined Detection of Orexin-A, HLA Gene, PSG and MSLT in the Evaluation of Patients With Narcole NCT04940806 | Qianfoshan Hospital | — |
| Completed | A Patient-Centric, Prospective, Observational, Non-Interventional Switch Study of XYWAV in Narcolepsy NCT04803786 | Jazz Pharmaceuticals | — |
| Completed | An Interventional Safety Switch Study (Segue Study) of XYWAV in Narcolepsy NCT04794491 | Jazz Pharmaceuticals | Phase 4 |
| Completed | Anesthetic Management of Patients With Chronic Sleep Disorders NCT04827329 | University Hospital, Montpellier | — |
| Completed | A Study to Collect Information of People With Narcolepsy in Spain NCT04667338 | Takeda | — |
| Recruiting | Child and Adolescent Registry for Participants With Narcolepsy NCT04899947 | Jazz Pharmaceuticals | — |
| Completed | Study to Evaluate the Abuse Liability, Pharmacokinetics, Safety and Tolerability of an Abuse-Deterrent d-Amphe NCT04647903 | Vallon Pharmaceuticals, Inc. | Phase 1 |
| Withdrawn | Evaluation of the Efficacy of Sodium Oxybate (Xyrem®) in Treatment of Post-traumatic Narcolepsy and Post-traum NCT03626727 | Brigham and Women's Hospital | EARLY_Phase 1 |
| Completed | Awareness and Self-Compassion Enhancing Narcolepsy Treatment NCT04306952 | Northwestern University | N/A |
| Completed | An Open Label Study of FT218 in Subjects With Narcolepsy NCT04451668 | Avadel | Phase 3 |
| Completed | TElemedicine for NARcolepsy NCT04316286 | Azienda Usl di Bologna | N/A |
| Completed | Study of the Academic and Professional Course of Narcoleptic Patients (NARCOSCOL-NARCOVITAE) NCT03765892 | Hospices Civils de Lyon | — |
| Recruiting | International Swiss Primary Hypersomnolence and Narcolepsy Cohort Study NCT04330963 | Insel Gruppe AG, University Hospital Bern | — |
| Completed | Advancing Understanding of Transportation Options NCT04141891 | University of Colorado, Denver | N/A |
| Suspended | 'A Profile of Physical Performance Variables in an Out-patient Adult Population With Narcolepsy' NCT04419792 | University of Dublin, Trinity College | — |
| Completed | A Study to Evaluate Safety, and Efficacy of SUVN-G3031 (Samelisant) in Patients With Narcolepsy With and Witho NCT04072380 | Suven Life Sciences Limited | Phase 2 |
| Recruiting | SUNOSI® (Solriamfetol) Pregnancy Registry NCT06413420 | Axsome Therapeutics, Inc. | — |
| Completed | Pilot Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Abuse Liability of an Abuse-Deterrent Imme NCT04232644 | Vallon Pharmaceuticals, Inc. | Phase 1 |
| Completed | Development and Validation of Pediatric Narcolepsy Patient Reported Outcomes Scale NCT05373979 | Boston Children's Hospital | — |
| Completed | Clinical Outcomes in Narcolepsy and Cataplexy: An Evaluation of Reboxetine Treatment (CONCERT) NCT03881852 | Axsome Therapeutics, Inc. | Phase 2 |
| Completed | Psychosocial Adjunctive Treatment for Hypersomnia (PATH) NCT03904238 | Northwestern University | N/A |
| Completed | A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of TAK-925 in Healthy Volu NCT03748979 | Takeda | Phase 1 |
| Unknown | Exploration of the Reward System by Functional MRI in Narco-cataplexy Patients With and Without REM Sleep Beha NCT03425214 | University Hospital, Clermont-Ferrand | N/A |
| Completed | A Study to Evaluate the Safety and Efficacy of TS-091 in Patients with Narcolepsy NCT03267303 | Taisho Pharmaceutical Co., Ltd. | Phase 2 |
| Completed | Evaluation of Academic and Professional Trajectories of Narcoleptic Patients NCT03173378 | Hospices Civils de Lyon | — |
| Completed | Once-Nightly Sodium Oxybate for Treatment of Excessive Daytime Sleepiness and Cataplexy in Narcolepsy NCT02720744 | Avadel | Phase 3 |
| Completed | The Effect of Caffeine on the Narcoleptic Patients NCT02832336 | King Saud University | Phase 1 / Phase 2 |
| Completed | Safety and Efficacy of THN102 on Sleepiness in Narcoleptic Patients NCT02821715 | Theranexus | Phase 2 |
| Completed | Study Assessing Effects of JZP-110 on Driving Performance in the Treatment of Excessive Sleepiness in Narcolep NCT02806908 | Jazz Pharmaceuticals | Phase 2 |
| Completed | Narcolepsy Protect Against Alzheimer's Disease? NCT03378453 | University Hospital, Montpellier | N/A |
| Completed | Sleep and Memory in Children NCT02785328 | Hospices Civils de Lyon | N/A |
| Unknown | Investigation of Clinical Feature and Brain Function in Narcoleptic Patients NCT03376568 | Tang-Du Hospital | — |
| Completed | Cardiovascular Variability and Heart Rate Arousal Response in Idiopathic Hypersomnia NCT02913651 | Centre Hospitalier Universitaire de Saint Etienne | — |
| Completed | A Web-based Observational Study of Patient-reported Outcomes in Adults With Narcolepsy NCT02769780 | Jazz Pharmaceuticals | — |
| Completed | "A Long-Term Safety Study of JZP-110 in the Treatment of Excessive Sleepiness in Subjects With Narcolepsy or O NCT02348632 | Jazz Pharmaceuticals | Phase 3 |
| Completed | "Twelve-week Study of the Safety and Efficacy of JZP-110 in the Treatment of Excessive Sleepiness in Narcoleps NCT02348593 | Jazz Pharmaceuticals | Phase 3 |
| Completed | This is a Study to Determine the Effect of Multiple Doses of an Investigational Drug, Taken by Mouth, in Peopl NCT05015673 | Otsuka Pharmaceutical Development & Commercialization, Inc. | Phase 1 |
| Completed | Metabolism Characteristics in the Children With Narcolepsy NCT02799849 | Hospices Civils de Lyon | N/A |
| Completed | Neurophysiologic Correlates of Hypersomnia NCT01719315 | University of Wisconsin, Madison | — |
| Completed | A Study of the Safety and Effectiveness of ADX-N05 for Excessive Daytime Sleepiness in Subjects With Narcoleps NCT01681121 | Jazz Pharmaceuticals | Phase 2 |
| Completed | Patient Narcoleptic Treated With BF2.649 (Pitolisant) in add-on to Sodium Oxybate (HARMONY IV) NCT01789398 | Bioprojet | Phase 3 |
| Completed | Study to Evaluate the Pharmacokinetics, Pharmacodynamics, and Safety of Armodafinil in Children and Adolescent NCT01624480 | Teva Branded Pharmaceutical Products R&D, Inc. | Phase 1 |
| Completed | A Study of the Safety and Effectiveness of ADX-N05 in the Treatment of Excessive Daytime Sleepiness NCT01485770 | Jazz Pharmaceuticals | Phase 2 |
| Completed | Risk of Narcolepsy Associated With Administration of H1N1 Vaccine NCT01394614 | Centre Integre Universitaire de Sante et Services Sociaux du Nord de l'ile de Montreal | — |
| Completed | Long Term Open Label Study in Narcolepsy With BF2.649 (Pitolisant) NCT01399606 | Bioprojet | Phase 3 |
| Completed | Clarithromycin for the Treatment of Hypersomnia NCT01146600 | Lynn Marie Trotti | Phase 2 |
| Completed | Method of Assessment of Driving Ability in Patients Suffering From Wakefulness Pathologies NCT00916253 | University Hospital, Bordeaux | N/A |
| Completed | A Study Of A Novel Compound For Excessive Daytime Sleepiness Associated With Narcolepsy NCT01006122 | Pfizer | Phase 2 |
| Completed | Efficacy and Safety Study of BF2.649 and BF2.649 Add on Modafinil on Cataplexy in Patients With Narcolespy NCT01067235 | Bioprojet | Phase 3 |
| Terminated | The Nuvigil and Provigil Pregnancy Registry NCT01792583 | Cephalon, Inc. | — |
| Completed | Efficacy and Safety Study of BF2.649 in the Treatment of Excessive Daytime Sleepiness in Narcolepsy NCT01067222 | Bioprojet | Phase 3 |
| Unknown | Effect of Intranasal Administration of Orexine A on IL-6-System, Sleep-Wake-Regulation and Neurocognition NCT00484757 | Zentrum für Integrative Psychiatrie | N/A |
| Completed | A Safety and Effectiveness Study of a Single Dose of JNJ-17216498 in Patients With Narcolepsy NCT00424931 | Alza Corporation, DE, USA | Phase 2 |
| Terminated | Effectiveness Of The Drug GSK189254 In Treating Patients With Narcolepsy NCT00366080 | GlaxoSmithKline | Phase 2 |
| Completed | Observational Study to Evaluate Risks of Side Effects, Drug Abuse and Dependence in Patients Who Received Xyre NCT00244465 | UCB Pharma | — |
| Completed | Body Weight Regulation in Patients With Narcolepsy NCT00283894 | National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) | — |
| Completed | Study to Assess Patient Reported Outcomes With Armodafinil Treatment for Excessive Sleepiness in Adults With N NCT00228566 | Cephalon | Phase 3 |
| Completed | Assess the Safety and Effectiveness of PROVIGIL Treatment in Children and Adolescents With Excessive Sleepines NCT00214968 | Cephalon | Phase 3 |
| Completed | Trial of Xyrem® (Sodium Oxybate) for the Treatment of Narcolepsy NCT00132873 | Jazz Pharmaceuticals | Phase 3 |
| Completed | PROVIGIL® (Modafinil) Treatment in Children and Adolescents With Excessive Sleepiness Associated With Narcolep NCT00107848 | Cephalon | Phase 3 |
| Completed | Study of PROVIGIL ® (Modafinil) Treatment in Children and Adolescents With Excessive Sleepiness Associated Wit NCT00107796 | Cephalon | Phase 3 |
| Completed | Extension Study of the Safety and Efficacy of Armodafinil in the Treatment of Patients With Excessive Sleepine NCT00228553 | Cephalon | Phase 3 |
| Completed | Safety and Efficacy Study of Armodafinil (CEP-10953) in the Treatment of Excessive Sleepiness Associated With NCT00078377 | Cephalon | Phase 3 |
| Completed | Armodafinil (CEP-10953) for Treatment of Narcolepsy, Obstructive Sleep Apnea/Hypopnea Syndrome, or Chronic Shi NCT00078312 | Cephalon | Phase 3 |
| Completed | Provigil (Modafinil) Study by Taiwan Biotech Co. NCT00174174 | National Taiwan University Hospital | N/A |
| Completed | Trial Comparing Effects of Xyrem Taken Orally and Modafinil With Placebo in Treating Daytime Sleepiness in Nar NCT00066170 | Jazz Pharmaceuticals | Phase 3 |
| Completed | Safety and Efficacy of Xyrem Oral Solution (Sodium Oxybate) Compared With Placebo in Narcoleptic Patients NCT00049803 | Orphan Medical | Phase 3 |
| Completed | Sleep Disorders of Patients With Diseases of the Nervous System NCT00001664 | National Institute of Neurological Disorders and Stroke (NINDS) | — |
| No Longer Available | Expanded Access to SUVN-G3031 (Samelisant) for the Treatment of Subjects With Narcolepsy NCT05530447 | Suven Life Sciences Limited | — |
| Unknown | Narcolepsy - New Potential Treatment NCT02077036 | Karolinska University Hospital | N/A |